A phase IIb study of extended-release formulation of SPN-812 in patients with attention deficit hyperactivity disorder (ADHD)
Phase of Trial: Phase II
Latest Information Update: 09 May 2017
At a glance
- Drugs Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 09 May 2017 According to a Supernus Pharmaceuticals media release, company is on track to meet with the FDA in the second quarter of 2017 for an end-of-Phase II meeting.
- 04 May 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2016 According to a Supernus Pharmaceuticals media release, status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History